Ganirelix regulatory status
Current status of Ganirelix in the United States: FDA approved. In sport: Not WADA prohibited. Details, sources, and the dated timeline follow.
By the PeptideAgent Editorial Team. Draft, pending editorial review. Last verified
What is the current status of Ganirelix?
Regulatory: FDA approvedWADA: Not WADA prohibitedVerified: Verified Sep 23, 2026
- FDA and compounding
- FDA approved prescription drug (originally Antagon, approved July 1999; now sold as Ganirelix Acetate Injection and generic and branded equivalents). Commercially available in prefilled syringes, so it is not eligible for routine compounding and is not on any 503A bulks list. Not a research chemical.
- WADA
- Not WADA prohibited
- Access path
- Prescription from a fertility specialist as part of an IVF or egg freezing protocol, filled at a specialty or fertility pharmacy.
- Not available through compounding pharmacies or telehealth peptide clinics.
Full Ganirelix page: evidence, dosing in the literature, and sources
How has the status of Ganirelix changed over time?
No dated regulatory event has been recorded for Ganirelix. That usually means no FDA, PCAC, Federal Register, or WADA action has named it specifically. Category-wide actions are listed on the tracker hub.
Sources
Numbered citations in the answers above point here, followed by the regulatory sources on record for Ganirelix and the source of each dated event.